Skip to main content
SpringerLink
Log in

As a result of the JUPITER trial, 65% of surveyed managed care organisation (MCO) pharmacy directors

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP. Media Release: 23 Feb 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

As a result of the JUPITER trial, 65% of surveyed managed care organisation (MCO) pharmacy directors. Pharmacoecon. Outcomes News 573, 10 (2009). https://doi.org/10.2165/00151234-200905730-00033

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905730-00033

Keywords

Search

Navigation